-
Mashup Score: 0AUA Amendment to Testicular Cancer Guideline Includes New Treatment Options, Imaging Recommendations - 7 month(s) ago
Many patients with low-stage disease have high survival rates, and the priority for those patients is reducing the burden of therapy and treatment-related toxicity without compromising the efficacy of their cancer treatment. The AUA reviewed new literature through their update literature review process and distributed it to peer reviewers of varying backgrounds. The literature was then approved by the AUA Board of Directors and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 4
The top-line results indicate a 20% lower relative risk of MACE on top of standard care.
Source: www.tctmd.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#BreakingNews: Semaglutide significantly reduces the rate of cardiovascular events in adults with overweight or obesity. The drug has already become popular for its weight loss effects. Read more from @ToddNeale: https://t.co/L7gWlG2DGJ https://t.co/kfqnvGdIxI
-
-
Mashup Score: 0
In a major breakthrough, Gilead’s remdesivir (Veklury) becomes the first COVID-19 antiviral to be FDA-approved for patients with severe renal disease.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
#BreakingNews: The FDA has approved remdesivir as the first and only antiviral COVID-19 treatment for patients with severe renal impairment. Learn more about this breakthrough and how it benefits those with kidney disease. https://t.co/rea7mV6iAK
-
-
Mashup Score: 1FDA Approves First Nonprescription Daily Birth Control Pill - 10 month(s) ago
The approval of norgestrel tablets (Opill) could open the door to other prescription-to-OTC contraceptive switches, although that remains to be seen as other pharmaceutical companies weigh their options.
Source: Pharmacy TimesCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The approval of norgestrel tablets (Opill) could open the door to other prescription-to-OTC #contraceptive switches, although that remains to be seen as other pharmaceutical companies weigh their options. #birthcontrol #breakingnews Read More: https://t.co/xJ6Sr6gHFA
-
-
Mashup Score: 0CDC Recommends RSV Vaccines for Older Adults - 10 month(s) ago
As of today, the new GSK and Pfizer RSV vaccines are authorized for adults 60 years and older. With CDC Director Dr. Rochelle Walensky’s endorsement, the vaccines are expected to be available as soon as this fall.
Source: ContagionLiveCategories: Infectious Disease, Latest HeadlinesTweet-
#BreakingNews: CDC Director Dr. Rochelle Walensky has recommended the GSK and Pfizer RSV vaccines for adults 60 years and older. https://t.co/15srfRPpo7
-
-
Mashup Score: 0Blinatumomab Receives Full Approval for MRD-Positive B-Cell ALL - 10 month(s) ago
The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia. #oncology #nursing #oncologynursing #FDA #approval #BreakingNews #leusm #ALL https://t.co/x69mBZCMmD
-
-
Mashup Score: 0New Study Shows a Coordinated Care Approach Significantly Improves Quality of Care for Patients with Type 2 Diabetes and Heart Disease | ADA - 10 month(s) ago
Data Addresses Gaps in Preventive Prescriptions Therapy, Emphasizing the Importance of Multifaceted InterventionsToday, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes…
Source: diabetes.orgCategories: Endocrinology, Latest HeadlinesTweet-
#BreakingNews: Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists & other team members can significantly increase the prescriptions of evidence-based therapies. https://t.co/rvddUMLGUH #ADA2023 https://t.co/CVO0Gn1q5W
-
-
Mashup Score: 4
Today, findings from two phase 2 clinical trials showcase new data for an investigational, once-weekly injectable glucose-dependent insulinotropic polypeptide (GIP)/ glucagon-like peptide 1 (GLP-1) /glucagon (GCG) receptor agonist, retatrutide. One study was conducted in people with obesity and included a substudy in patients who also had non-alcoholic fatty liver disease (NAFLD) and the second…
Source: diabetes.orgCategories: Endocrinology, Latest HeadlinesTweet-
#BreakingNews: Phase 2 clinical trials showcase new data for an investigational, once-weekly injectable glucose-dependent insulinotropic polypeptide (GIP)/ glucagon-like peptide 1 (GLP-1) /glucagon (GCG) receptor agonist, retatrutide. https://t.co/rjdF04hEPe #ADA2023 https://t.co/vjq3q1UUhD
-
-
Mashup Score: 4Late Breaking Weight Loss Innovations: New Drug Therapies Shown to Offer Positive Outcomes for Obesity and Type 2 Diabetes Management | ADA - 10 month(s) ago
Novel Drug Treatment for Obesity Shown Effective Up to 46 Weeks Results from a phase 2 clinical trial of survodutide (also known as BI 456906), a novel dual glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) agonist, showed up to 18.7% weight loss in overweight or obese individuals through a 46-week time frame. The randomized, double-blind, placebo-controlled, dose-finding…
Source: diabetes.orgCategories: Endocrinology, Latest HeadlinesTweet-
#BreakingNews: Late breaking data focused on new drug therapy innovations to treat obesity were presented at #ADA2023. Oral semaglutide demonstrates weight loss up to 15% for people with #obesity and improved management of #T2D. Read more at https://t.co/4xUFL8lpt3. https://t.co/QgRvRoDqdR
-
#BreakingNews: Late breaking data focused on new drug therapy innovations to treat obesity were presented at #ADA2023. Oral semaglutide demonstrates weight loss up to 15% for people with #obesity and improved management of #T2D. Read more at https://t.co/oL6HaIsQwC. https://t.co/vTDLV1L7zp
-
-
Mashup Score: 5American Diabetes Association Releases Updates to the 2023 Standards of Care in Diabetes on the Use of Teplizumab in Delaying the Onset of Type 1 Diabetes | ADA - 10 month(s) ago
Today, the American Diabetes Association® (ADA) published updates to the Standards of Care in Diabetes—2023 (Standards of Care) on the use of teplizumab in delaying the onset of type 1 diabetes. Type 1 diabetes is a chronic autoimmune disease that affects millions of people worldwide, and its incidence is increasing. Teplizumab is a monoclonal antibody that targets the immune system and has been…
Source: diabetes.orgCategories: Endocrinology, Latest HeadlinesTweet-
#BreakingNews: Today, the American Diabetes Association® published updates to the Standards of Care in Diabetes—2023 on the use of #teplizumab in delaying the onset of type 1 diabetes. Learn more at https://t.co/SOAKwyxw2r. #ADA2023 #SOC2023 #ConnectedForLife https://t.co/cUKSbaM3cg
-
New guideline updates have been made to the @AmerUrological guideline for the diagnosis and treatment of early-stage #testicularcancer. The updates include new information on treatment, imaging, and more: https://t.co/QGSbcEBglP #BreakingNews https://t.co/lRiyTkqlK7